# Okayama University Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/okayama-university-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 48 |
| Citations | 361,921 |
| City | Okayama |
| Country | JP |
| Description | Okayama University Hospital is a research organisation in Okayama, JP. OpenAlex records 8,899 works and 361,921 citations for it. 1,883 researchers list it as their most recent affiliation. |
| Homepage | http://www.hsc.okayama-u.ac.jp/hos/en/ |
| OpenAlex ID | https://openalex.org/I4210100185 |
| Researchers | 1,883 |
| ROR ID | https://ror.org/019tepx80 |
| Type | healthcare |
| Works | 8,899 |

## University papers

Showing 12 of 44.

- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus/)
- [The classification of glomerulonephritis in systemic lupus erythematosus revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus-2/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Inflammation and the pathogenesis of diabetic nephropathy](https://scholariq.org/papers/inflammation-and-the-pathogenesis-of-diabetic-nephropathy/)
- [Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system](https://scholariq.org/papers/uric-acid-stimulates-vascular-smooth-muscle-cell-proliferation-and-oxidative/)
- [Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity](https://scholariq.org/papers/visceral-adipose-tissue-derived-serine-protease-inhibitor-a-unique-insulin/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease](https://scholariq.org/papers/estimation-of-glomerular-filtration-rate-by-the-mdrd-study-equation-modified-for/)
- [Prevalence of chronic kidney disease in the Japanese general population](https://scholariq.org/papers/prevalence-of-chronic-kidney-disease-in-the-japanese-general-population/)

## University researchers

- [Hirofumi Makino](https://scholariq.org/researchers/hirofumi-makino/)
- [Kazuyuki Matsumoto](https://scholariq.org/researchers/kazuyuki-matsumoto/)
- [Shigeru Horiguchi](https://scholariq.org/researchers/shigeru-horiguchi/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.